Heartflow, Inc. (NASDAQ:HTFL) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Heartflow, Inc. (NASDAQ:HTFL) has been given an average rating of "Moderate Buy" by six analysts, with a 12-month price target of $36.60.
• The company's recent quarterly earnings report showed a loss of ($1.46) earnings per share, missing estimates, but it generated revenue of $43.42 million, slightly surpassing predictions.
• Heartflow's stock performance has fluctuated between a 1-year low of $26.56 and a high of $36.68.

Shares of Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) have received an average rating of "Moderate Buy" from the six analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $36.60.

HTFL has been the topic of a number of analyst reports. Zacks Research upgraded Heartflow to a "hold" rating in a report on Wednesday, September 3rd. Wall Street Zen upgraded Heartflow to a "hold" rating in a report on Saturday, August 16th. Morgan Stanley initiated coverage on Heartflow in a report on Tuesday, September 2nd. They set an "equal weight" rating and a $35.00 target price on the stock. Piper Sandler initiated coverage on Heartflow in a report on Tuesday, September 2nd. They set an "overweight" rating and a $38.00 target price on the stock. Finally, Canaccord Genuity Group increased their target price on Heartflow from $35.00 to $39.00 and gave the company a "buy" rating in a report on Monday, September 22nd.

Heartflow Price Performance

HTFL opened at $33.06 on Friday. Heartflow has a 1-year low of $26.56 and a 1-year high of $36.68.

Heartflow (NASDAQ:HTFL - Get Free Report) last released its quarterly earnings results on Friday, September 19th. The company reported ($1.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($1.26). The company had revenue of $43.42 million during the quarter, compared to analyst estimates of $43.20 million.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.